|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...87888990919293949596979899» |
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK, Rotarix (rotavirus vaccine) / GSK
Trial completion: Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants (clinicaltrials.gov) - Oct 20, 2011
P2, N=480, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed
- Clinical: Computertomography-guided Wire Marking of the Liver (clinicaltrials.gov) - Oct 20, 2011
P=N/A, N=20, Recruiting, Sponsor: Medical University of Graz
- |||||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
New P3 trial: Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine (clinicaltrials.gov) - Oct 19, 2011
P3, N=80, Completed, Sponsor: GlaxoSmithKline
- Pegasys (pegylated interferon α -2a) / Roche, ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Trial completion: MEN_EPID: Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C (clinicaltrials.gov) - Oct 19, 2011
P=N/A, N=1000, Completed, Sponsor: Prof. Facchinetti Fabio
Active, not recruiting --> Completed Recruiting --> Completed
- Kuvan (sapropterin) / Merck (MSD), BioMarin, Daiichi Sankyo
New P2/3 trial: Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension (clinicaltrials.gov) - Oct 18, 2011
P2/3, N=42, Completed, Sponsor: Fundacion Clinic per a la Recerca Biomédica
- ||||| beclabuvir (BMS-791325) / BMS, Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
New P2 trial, Combination therapy: Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications (clinicaltrials.gov) - Oct 17, 2011
P2, N=316, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- |||| Enrollment open: Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials (clinicaltrials.gov) - Oct 16, 2011
P2, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
New P3 trial: Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine (clinicaltrials.gov) - Oct 13, 2011
P3, N=252, Completed, Sponsor: Novartis
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial completion: Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children (clinicaltrials.gov) - Oct 13, 2011
P4, N=300, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- thalidomide / Generic mfg., tegafur/uracil / Generic mfg.
Trial completion, Metastases: UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 13, 2011
P2, N=44, Completed, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- ||| valacyclovir / Generic mfg.
New P1 trial: Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I) (clinicaltrials.gov) - Oct 13, 2011
P1, N=125, Recruiting, Sponsor: Department of Veterans Affairs
- | Enrollment change: Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis (clinicaltrials.gov) - Oct 12, 2011
P1/2, N=20, Completed, Sponsor: Shenzhen Beike Bio-Technology Co., Ltd.
Recruiting --> Completed N=50 --> 20
- ||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
New P2 trial: Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly (clinicaltrials.gov) - Oct 12, 2011
P2, N=312, Completed, Sponsor: GlaxoSmithKline
- | Trial completion: Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis (clinicaltrials.gov) - Oct 12, 2011
P1/2, N=20, Completed, Sponsor: Shenzhen Beike Bio-Technology Co., Ltd.
N=50 --> 20 Recruiting --> Completed
- New P2/3 trial: Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion (clinicaltrials.gov) - Oct 12, 2011
P2/3, N=0, Withdrawn, Sponsor: Vital Therapies, Inc.
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change, Pre-transplantation: Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 11, 2011
P1, N=40, Active, not recruiting, Sponsor: Northwestern University
Recruiting --> Completed N=20 --> 40
- Trial completion: Relation of Obesity With Frequency of Meals (MST 0557) (clinicaltrials.gov) - Oct 11, 2011
P=N/A, N=22, Completed, Sponsor: Rockefeller University
N=20 --> 40 Active, not recruiting --> Completed
- | thalidomide / Generic mfg.
Trial termination, Metastases: Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve (clinicaltrials.gov) - Oct 10, 2011
P3, N=230, Terminated, Sponsor: TTY Biopharm
Active, not recruiting --> Completed Recruiting --> Terminated; slowly recruitment rate
- |||| Hepatoren (ifetroban) / Cumberland
Enrollment open: Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients (clinicaltrials.gov) - Oct 10, 2011
P2, N=64, Recruiting, Sponsor: Cumberland Pharmaceuticals
Recruiting --> Terminated; slowly recruitment rate Not yet recruiting --> Recruiting
- mitomycin / Generic mfg., doxorubicin hydrochloride / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Combination therapy, Surgery: Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Oct 10, 2011
P1, N=11, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- pioglitazone / Generic mfg.
Enrollment change: Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance (clinicaltrials.gov) - Oct 5, 2011
P2, N=19, Completed, Sponsor: AIDS Clinical Trials Group
Recruiting --> Active, not recruiting N=30 --> 19
- |||||||||| Daklinza (daclatasvir) / BMS
New P3 trial, Combination therapy: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C (clinicaltrials.gov) - Oct 5, 2011
P3, N=120, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- | GSK 2336805 / J&J
New P1 trial: Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults (clinicaltrials.gov) - Oct 5, 2011
P1, N=28, Completed, Sponsor: GlaxoSmithKline
- Enrollment change: Lactate Metabolism Study in HIV Infected Persons (clinicaltrials.gov) - Oct 4, 2011
P4, N=30, Completed, Sponsor: Queen's University
N=30 --> 19 N=40 --> 30
- ||| Asclevir (ravidasvir) / Presidio Pharma, Ascletis, Pharco Pharmaceuticals
New P1 trial: A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1 (clinicaltrials.gov) - Oct 4, 2011
P1, N=82, Completed, Sponsor: Presidio Pharmaceuticals, Inc.
- Trial completion: Lactate Metabolism Study in HIV Infected Persons (clinicaltrials.gov) - Oct 4, 2011
P4, N=30, Completed, Sponsor: Queen's University
N=40 --> 30 Active, not recruiting --> Completed
- peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University
New P3 trial, Combination therapy: Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C (clinicaltrials.gov) - Oct 3, 2011
P3, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
- |||||||||| alisporivir (DEB-025) / Debiopharm, Solid BioSci
New P3 trial, Combination therapy: Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Oct 3, 2011
P3, N=210, Completed, Sponsor: Novartis Pharmaceuticals
- | miravirsen (SPC3649) / BMS
Trial completion: SPC3649 Multiple Dose Study in Healthy Volunteers (clinicaltrials.gov) - Oct 3, 2011
P1, N=30, Completed, Sponsor: Santaris Pharma A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Biomarker: GBMC Triage Study: Prognostic Indicators as Provided by the EPIC ClearView (clinicaltrials.gov) - Oct 2, 2011
P=N/A, N=353, Completed, Sponsor: Epic Research & Diagnostics, Inc.
- | New P2 trial: Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Oct 2, 2011
P2, N=66, Completed, Sponsor: Bambino Ges
- | INX 189 / BMS
New P1/2 trial: Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-na (clinicaltrials.gov) - Oct 2, 2011
P1/2, N=50, Completed, Sponsor: Bristol-Myers Squibb
- |||||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
New P3 trial, IO biomarker: Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants (clinicaltrials.gov) - Sep 29, 2011
P3, N=1106, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- | Kremezin (AST-120) / Mitsubishi Tanabe
Trial completion: AST015: Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy (clinicaltrials.gov) - Sep 28, 2011
P2, N=40, Completed, Sponsor: Ocera Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Enrollment change: Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors (clinicaltrials.gov) - Sep 28, 2011
P1, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=16 --> 12 | Recruiting --> Completed
- Victrelis (boceprevir) / Roche, Merck (MSD)
New P4 trial: Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV (clinicaltrials.gov) - Sep 28, 2011
P4, N=200, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | BIIB022 / Biogen
Trial completion, Metastases: Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Sep 28, 2011
P1, N=40, Completed, Sponsor: Biogen Idec
N=16 --> 12 | Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors (clinicaltrials.gov) - Sep 28, 2011
P1, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed
- Clinical: Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis (clinicaltrials.gov) - Sep 27, 2011
P=N/A, N=30, Not yet recruiting, Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Trial termination: EXACT-R(3): EXtended Therapy in Hepatitis C Genotype 3 Infected Patients (clinicaltrials.gov) - Sep 27, 2011
P3, N=2, Terminated, Sponsor: University Health Network, Toronto
Recruiting --> Completed Recruiting --> Terminated; Unlikely to recruit the adequate number of patients within a reasonable timeline
- Enrollment change: EXACT-R(3): EXtended Therapy in Hepatitis C Genotype 3 Infected Patients (clinicaltrials.gov) - Sep 27, 2011
P3, N=2, Terminated, Sponsor: University Health Network, Toronto
Recruiting --> Terminated; Unlikely to recruit the adequate number of patients within a reasonable timeline N=146 --> 2
- pidilizumab (CT-011) / CureTech
Trial termination: Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 26, 2011
P1/2, N=2, Terminated, Sponsor: CureTech Ltd
N=146 --> 2 Active, not recruiting --> Terminated; The study was stopped because of slow accrual
- Enrollment closed: Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC) (clinicaltrials.gov) - Sep 26, 2011
P=N/A, N=25, Active, not recruiting, Sponsor: Angiodynamics, Inc.
Active, not recruiting --> Terminated; The study was stopped because of slow accrual Recruiting --> Active, not recruiting
- Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Enrollment change, Metastases: Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer (clinicaltrials.gov) - Sep 26, 2011
P2, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=44 --> 19
- || Enrollment change: EPIC B: Epidemiological Study in Children and Adolescents With Chronic Hepatitis B (clinicaltrials.gov) - Sep 25, 2011
P=N/A, N=1640, Completed, Sponsor: Novartis Pharmaceuticals
N=44 --> 19 N=3000 --> 1640
- L-ornithine-L-aspartate / Generic mfg.
New P2/3 trial: The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS (clinicaltrials.gov) - Sep 25, 2011
P2/3, N=40, Completed, Sponsor: Fourth Military Medical University
- ||| Trial completion: EPIC B: Epidemiological Study in Children and Adolescents With Chronic Hepatitis B (clinicaltrials.gov) - Sep 25, 2011
P=N/A, N=1640, Completed, Sponsor: Novartis Pharmaceuticals
N=3000 --> 1640 Active, not recruiting --> Completed
- | ribavirin / Generic mfg.
New P1/2 trial, Combination therapy: GS-7977 With Ribavirin for Hepatitis C (SPARE) (clinicaltrials.gov) - Sep 25, 2011
P1/2, N=79, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- grazoprevir (MK-5172) / Merck (MSD)
New P2 trial: Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) (clinicaltrials.gov) - Sep 22, 2011
P2, N=5, Terminated, Sponsor: Merck
- Enrollment open, Surgery: PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection (clinicaltrials.gov) - Sep 21, 2011
P1/2, N=80, Recruiting, Sponsor: Queen's Medical Centre
Active, not recruiting --> Completed Not yet recruiting --> Recruiting